Objective: to evaluate the efficiency of using the immunomodulator galavit in the combination therapy of puerperas with pyoseptic complications, by investigating the diagnostic markers of inflammation. Subjects and methods. Group 1 included 25 puerperas with pyoseptic complications who received combination antibacterial therapy using the immunomodulatory galavit (a study group); Group 2 consisted of 25 puerperas with pyoseptic complications who took no immunomodulators (a comparative group). A control group comprised 20 healthy puerperas with the physiological course of the postpartum period. All the puerperas underwent bacteriological tests, general blood analysis, leukocyte intoxication index calculation, procalcitonin determination, and testing for TORCH infection pathogens. Results. It was ascertained that leukocytes with the appearance of their immature forms; a more than 6-fold increase in leukocyte intoxication index; procalcitonin levels of higher than 2 ng/ml; depression of T-cell immunity with decreased T-lymphocyte functional activity; compensatory activation of humoral immunity with an increase in the count of B lymphocytes and in the levels of IgM and circulating immune complexes were detected in puerperas with viral and bacterial pyoseptic complications. In this case, traditional therapy aggravated T-cell depression. Incorporation of the immunomodulatory galavit into the combination treatment of patients with postpartum pyoseptic complications leads to higher cellular immunity indicators, stabilized humoral immunity, and shorter disease duration. Conclusion. The immunomodulatory galavit is an effective agent for the treatment of puerperas with pyoseptic complications; its use leads to shorter treatment times, and a lower risk for recurrent pyoseptic diseases and a chronic process. The authors declare no conflicts of interest.